Brentuximab Vedotin Demonstrates Activity in a Patient With Plasmablastic Lymphoma Arising From a Background of Chronic Lymphocytic Leukemia

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research · 2004 · 1.2K citations

Pharmacy, Oncology, Pharmacology +17

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · Journal of Clinical Oncology · 2012 · 990 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Plasmablastic Lymphomas of the Oral Cavity: A New Entity Associated With the Human Immunodeficiency Virus Infection

Henri‐Jacques Delecluse, I. Anagnostopoulos, F Dallenbach et al. · Blood · 1997 · 865 citations · Full text

Dentistry, Oral Pathology, Oral Immunology +11

Diffuse Large B-cell Lymphomas With Plasmablastic Differentiation Represent a Heterogeneous Group of Disease Entities

Luís Colomo, Florence Loong, Susana Rives et al. · The American Journal of Surgical Pathology · 2004 · 414 citations

Medicine, Hematology, Oncology +14